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universally beneficial for patients with this syndrome. We ought to 
remember that the term "syndrome X" is a descriptive t rm only, and 
a poor one indeed. Syndrome X is a heterogeneous entity, and 
different patient subgroups have now been identified. In some patients, 
symptoms may be caused by myocardial ischemia or microvascular 
endothelial dysfunction, or both; in others by increased pain percep- 
tion, estrogen deficiency, psychologic disturbances or a combination of 
these. Patients with insulin resistance may represent another pathoge- 
netic subgroup. However, the proportion of patients with syndrome X
in whom insulin resistance isresponsible for the clinical manifestations 
is not yet known. 
A trial of metabolic therapy, as suggested by Seery, may be 
justifiable in syndrome X. However, this approach is likely to succeed 
in only those patients whose symptoms are caused by the metabolic 
disorder but not in every patient with angina and normal coronary 
arteriographic findings. Too often since the initial description of 
syndrome X have investigators mistakingly attempted to identify a 
single etiologic mechanism for this heterogeneous condition. Let us 
not fall into this trap yet again. 
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Assessment of Cardiovascular 
Autonomic Function 
I read the report by Zarich et al. (1) with immense interest. However, 
I am concerned about the methodology, used in testing the autonomic 
function of their patients. The cutoff points for an "abnormal" test 
result for the Valsalva maneuver and the systolic blood pressure 
response to standing were taken as 1.25 and 20 mm Hg, respectively. In 
fact, these should be 1.10 for the Valsalva maneuver and 30 mm Hg for 
a decrease in systolic blood pressure (2). Zarich et al. did not take into 
consideration the heart rate response to standing, which tests the 
parasympathetic autonomic nervous ystem. The involvement of the 
parasympathetic autonomic nervous ystem is inferred by Zarich et al. 
to be more involved in diabetic autonomic neuropathy, causing the 
circadian pattern of myocardial isehemia. Again, the autonomic score 
is given as 0, 1 or 2, depending on whether a test result is normal, 
borderline or abnormal (3). A "battery" of at least five autonomic tests 
should be performed rather than the four used by Zarich et al. because 
no single test is sensitive enough to detect and classify types of 
autonomic dysfunction (3). Despite the battery of five autonomic tests, 
-6% of patients with autonomic insufficiency are unclassifiable and 
are grouped as "atypical" (2,3). I note that the Valsalva maneuver was 
performed only once, whereas a mean of three successive maneuvers i  
recommended (4). Such tests would stratify patients differently, and 
the differences in circadian patterns of ambulatory myocardial isch- 
emia between groups I and II in the Zarich et al. study might therefore 
not hold true. 
The frequency of silent myocardial ischemia in patients with 
autonomic insufficiency may be explained by a higher pain sensitivity 
threshold and ischemia tolerance in diabetic patients with autonomic 
neuropathy (5,6). In experimental nimals, a "denervation supersen- 
sitivity," causing enhanced sensitivity to the action of the sympathetic 
nervous ystem may occur (7). Pericardial prostaglandins released in 
the pericardial fluid, modulating the sympathetic effects of the heart, is 
an interesting hypothesis (7). Myocardial ischemia s the cause rather 
than the effect of neuropathy, including autonomic neuropathy, par- 
ticularly in early myocardial ischemia, is an exciting new concept and 
requires further confirmation (8,9). 
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Reply 
Siddiqui asserts that there is one battery of cardiovascular tests of the 
autonomic nervous ystem with universally accepted cutoffs between 
normal and abnormal test results. In reality, there are a number of 
different ests assessing cardiovascular utonomic function and no 
single established battery (1-3). Any test used to assess cardiovascular 
autonomic function should have acceptable sensitivity, specificity and 
reproducibility. Some investigators (2-4) have reported, for example, 
that the heart rate response to standing, a test advocated by Siddiqui, 
does not fulfill these criteria. The four tests that we used in our study 
to measure autonomic function satisfy the sensitivity, specificity and 
